Novel glutamine-hydrolyzing GMP synthase variant and method for producing purine nucleotides using the same

By creating glutamine hydrolyzing GMP synthase mutants that alter the 29th amino acid, the production of purine nucleotides like GMP and XMP is enhanced, addressing the inefficiencies in existing production methods and achieving higher yields.

JP2024161506AInactive Publication Date: 2024-11-19CJ CHEILJEDANG CORP
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2024135857
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-09-23
Filing Date
2024-08-16
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a need for more efficient production methods of purine nucleotides, which are used as food seasoning additives, as existing technologies do not adequately address the demand for high yields and production efficiency.

Method used

Development of glutamine hydrolyzing GMP synthase mutants, specifically altering the 29th amino acid in the GMP synthase enzyme from Corynebacterium species, to enhance the production of purine nucleotides such as GMP and XMP.

Benefits of technology

The mutants significantly increase the yield of purine nucleotides, particularly GMP, by improving the enzyme's activity and production capacity in microorganisms like Corynebacterium stationis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161506000001
    Figure 2024161506000001
  • Figure 2024161506000002
    Figure 2024161506000002
  • Figure 2024161506000003
    Figure 2024161506000003
Patent Text Reader

Abstract

To provide a glutamine-hydrolyzing GMP synthase variant that enables the production of purine nucleotides with high yield.SOLUTION: The present invention provides a glutamine-hydrolyzing GMP synthase variant with a specific amino acid sequence in which the amino acid corresponding to position 29 is substituted with another amino acid.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a glutamine hydrolyzing GMP synthetase mutant and a method for producing purine nucleotides using the same. [Background technology]

[0002] Purine nucleotides, which are one type of nucleic acid-based substance, are substances that are widely used as food seasoning additives or for food use, and have been attracting attention as tasty nucleic acid-based seasonings.

[0003] In order to produce purine nucleotides, various studies have been conducted to develop highly efficient production microorganisms and fermentation process technologies. For example, target substance-specific approaches such as increasing the expression of genes encoding enzymes involved in the biosynthesis of purine nucleotides or removing genes unnecessary for biosynthesis are mainly used (EP 3722430 A1, US 2020-0347346 A1).

[0004] As the demand for purine nucleotides increases, there remains a need for research into the efficient production of purine nucleotides. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] EP 3722430 A1 [Patent Document 2] US 2020-0347346 A1 [Patent Document 3] US Patent US 7662943 B2 [Patent Document 4] US Patent US 10584338 B2 [Patent Document 5] US Patent US 10273491 B2 [Patent Document 6] Korean Patent KR 10-0655902 B1

Patent document 7

Patent document 8

Non-licensed literature

[0006] [Non-licensed document 1] Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444 [Non-licensed document 2] Rice et al., 2000, Trends Genet. 16: 276-277 [Non-licensed document 3] Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453

Non-licensed Document 4

Non-licensed Document 5

Non-licensed Document 6

Non-licensed Document 7

Non-licensed literature 9

[0007] The present invention provides glutamine hydrolyzing GMP synthetase mutants. [Means for solving the problem]

[0008] An object of the present invention is to provide a glutamine hydrolyzing GMP synthase mutant.

[0009] It is another object of the present invention to provide polynucleotides encoding said variants.

[0010] Another object of the present invention is to provide a microorganism containing said mutant or a polynucleotide encoding same.

[0011] Another object of the present invention is to provide a method for producing purine nucleotides, which comprises the step of culturing said microorganism. Effect of the Invention

[0012] The mutants of the present invention can be used to produce purine nucleotides in high yields. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] The present invention will be described in detail as follows. Meanwhile, each description and embodiment disclosed in this specification may be applied to each different description and embodiment. That is, all combinations of the various elements disclosed in this specification are within the scope of this specification. Furthermore, the scope of the present invention is not limited by the specific description described below. Furthermore, numerous papers and patent documents are referenced throughout this specification, and citations thereof are provided. The disclosure contents of the cited papers and patent documents are incorporated by reference in their entirety into this specification to more clearly explain the state of the art to which the present invention pertains and the contents of the present invention.

[0014] One aspect of the present invention provides a mutant glutamine hydrolyzing GMP synthetase in which the amino acid corresponding to position 29 of SEQ ID NO:3 has been substituted with another amino acid.

[0015] The glutamine hydrolyzing GMP synthetase mutant refers to a polypeptide having glutamine hydrolyzing GMP synthetase activity or a mutant glutamine hydrolyzing GMP synthetase comprising a substitution of the amino acid corresponding to the 29th position from the N-terminus of SEQ ID NO: 3 with another amino acid.

[0016] In the present invention, the term "glutamine-hydrolyzing GMP synthase" refers to an enzyme that converts 5'-xanthosine monophosphate (XMP) into 5'- An enzyme involved in converting guanine acid (5'-guanosine monophosphate; hereafter referred to as GMP) It is.

[0017] The glutamine hydrolyzing GMP synthetase of the present invention may be a glutamine hydrolyzing GMP synthetase or a polypeptide having glutamine hydrolyzing GMP synthetase activity that is modified to produce a glutamine hydrolyzing GMP synthetase mutant provided by the present invention.

[0018] Specifically, it may be a naturally occurring or wild-type polypeptide, may be a mature polypeptide thereof, or may include a mutant or functional fragment thereof, but is included without limitation as long as it can serve as a parent of the glutamine hydrolyzing GMP synthetase mutant of the present invention.

[0019] In one embodiment, the glutamine hydrolyzing GMP synthase of the present invention may be derived from the genus Corynebacterium, more specifically, from Corynebacterium stationis, but is not limited thereto.

[0020] In one embodiment, the glutamine hydrolyzing GMP synthetase of the present invention may be a polypeptide of SEQ ID NO: 3. In one embodiment, the glutamine hydrolyzing GMP synthetase of the present invention may be a polypeptide having about 60%, 70%, 75%, 80%, 85%, 90%, 93%, 95%, 96%, 97%, 98%, or 99% or more sequence identity with the polypeptide of SEQ ID NO: 3, and is included in the scope of the glutamine hydrolyzing GMP synthetase without limitation as long as it has the same or corresponding activity as the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3. Specifically, the glutamine hydrolyzing GMP synthetase may have, include, or be essentially consisting of the amino acid sequence set forth in SEQ ID NO: 3, but is not limited thereto.

[0021] The glutamine hydrolyzing GMP synthetase to be mutated in the present invention may be a glutamine hydrolyzing GMP synthetase derived from Corynebacterium sp., specifically, a polypeptide / protein containing the amino acid sequence set forth in SEQ ID NO: 3, but may include any polypeptide / protein having the same activity without limitation. As an example, the glutamine hydrolyzing GMP synthetase may include, but is not limited to, the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence having 80% or more homology or identity thereto. Specifically, the glutamine hydrolyzing GMP synthetase may include an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or more homology or identity thereto. It is also self-evident that a polypeptide / protein having an amino acid sequence in which a part of the sequence is deleted, modified, substituted, or added is also included within the scope of the polypeptide / protein to be mutated in the present application, so long as it has such homology or identity and exhibits glutamine hydrolyzing GMP synthetase activity.

[0022] The sequence of the glutamine hydrolyzing GMP synthetase of the present invention can be obtained from the publicly known database, GenBank of NCBI. As an example, the glutamine hydrolyzing GMP synthetase of the present invention may be a polypeptide encoded by the guaA gene. As an example, the glutamine hydrolyzing GMP synthetase of the present application may be derived from Corynebacterium stationis, Corynebacterium casei, or Corynebacterium ammoniagenes, and examples thereof may include, but are not limited to, the enzymes shown in NCBI Reference sequence WP_194285183.1, WP_006823296.1, or WP_040355890.1.

[0023] In the present invention, the term "homology" or "identity" refers to the degree of similarity between two given amino acid or nucleotide sequences, which can be expressed as a percentage. The terms homology and identity can often be used interchangeably.

[0024] Sequence homology or identity of conserved polynucleotides or polypeptides may be determined by standard sequence algorithms, with default gap penalties established by the program used. Substantially homologous or identical sequences can generally hybridize to all or part of the sequence under moderate or high stringent conditions. Hybridization obviously includes hybridization to polynucleotides containing common codons in polynucleotides or codons that take into account codon degeneracy.

[0025] Whether any two polynucleotide or polypeptide sequences have homology, similarity or identity can be determined using known computer algorithms such as the "FASTA" program using default parameters, for example, as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, it can be determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453), as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later), (GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO ET AL.] (1988) SIAM J Applied Math 48: 1073. For example, BLAST or ClustalW from the National Database Center for Biotechnology Information can be used to determine homology, similarity or identity.

[0026] Homology, similarity or identity of polynucleotides or polypeptides can be determined by comparing sequence information using the GAP computer program, e.g., Needleman et al. (1970), J Mol Biol. 48:443, as known in, e.g., Smith and Waterman, Adv. Appl. Math (1981) 2:482. In summary, the GAP program can be defined as the total number of symbols in the shorter of the two sequences divided by the number of similar aligned symbols (i.e., nucleotides or amino acids). Default parameters for the GAP program include: (1) a binary comparison matrix (containing a value of 1 for identity and 0 for non-identity) and the weighted comparison matrix of Gribskov et al. (1986) Nucl. Acids Res. 14: 6745 (or the EDNAFULL (the EMBOSS version of NCBI NUC4.4) substitution matrix) as disclosed by Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap (or a gap open penalty of 10, a gap extension penalty of 0.5); (3) no penalty for end gaps.

[0027] In the present invention, the term "variant" refers to a polypeptide in which one or more amino acids are conservatively substituted and / or modified, and which differs from the amino acid sequence of the variant before the mutation, but maintains its functions or properties. Such a variant may generally be identified by modifying one or more amino acids in the amino acid sequence of the polypeptide and evaluating the properties of the variant. That is, the ability of the variant may be increased, unchanged, or decreased compared to the polypeptide before the mutation. In addition, some variants may include variants in which one or more portions, such as an N-terminal leader sequence or a transmembrane domain, have been removed. Other variants may include variants in which a portion has been removed from the N- and / or C-terminus of a mature protein. The term "variant" may be used interchangeably with terms such as mutant, modified, mutant polypeptide, mutant protein, mutation, and variant (in English, modification, modified polypeptide, modified protein, mutant, mutein, divergent, etc.), and is not limited to these terms as long as they are used in the sense of being mutated.

[0028] The variant may also include deletions or additions of amino acids that have minimal effect on the properties and secondary structure of the polypeptide. For example, the N-terminus of the variant may be conjugated to a signal (or leader) sequence involved in co-translationally or post-translationally protein translocation. The variant may also be conjugated to other sequences or linkers to allow identification, purification, or synthesis.

[0029] The glutamine hydrolyzing GMP synthetase mutant provided by the present invention may be a polypeptide comprising an amino acid sequence in which the amino acid corresponding to position 29 of SEQ ID NO: 3 has been substituted with another amino acid. Specifically, the other amino acid may be selected from glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, and histidine.

[0030] The "other amino acid" is not limited as long as it is an amino acid different from the amino acid before substitution. On the other hand, when it is expressed in the present invention that "a specific amino acid is substituted", it is self-evident that the amino acid before substitution is substituted with an amino acid different from the amino acid before substitution, even if it is not specifically stated that the amino acid is substituted with another amino acid.

[0031] In one embodiment, the variant of the present invention may be a variant in which the amino acid corresponding to the 29th position in the amino acid sequence of SEQ ID NO: 3, which is a reference protein, is an amino acid other than arginine. Specifically, the amino acid corresponding to the 29th position in SEQ ID NO: 3 of the variant may be selected from glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, and histidine.

[0032] In one embodiment, the glutamine hydrolyzing GMP synthetase mutant of the present invention may include an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7% or 99.8% homology or identity to the amino acid sequence of SEQ ID NO:3, where the amino acid corresponding to the 29th position of the amino acid sequence of SEQ ID NO:3 is an amino acid other than arginine.

[0033] By way of example, a glutamine hydrolyzing GMP synthetase mutant of the invention may comprise, but is not limited to, the amino acid sequence of SEQ ID NO:1 or an amino acid sequence having 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, or 99.8% or more identity thereto.

[0034] It is also obvious that variants having an amino acid sequence in which a portion of the sequence has been deleted, modified, substituted, conservatively substituted or added are also included within the scope of the present invention, so long as the variant has such homology or identity and exhibits efficacy corresponding to the variant of the present invention. For example, there may be additions or deletions of sequences at the N-terminus, C-terminus and / or internally of the amino acid sequence that do not alter the function of the variant of the present invention, naturally occurring mutations, silent mutations or conservative substitutions.

[0035] The term "conservative substitution" refers to the replacement of an amino acid with another amino acid having similar structural and / or chemical properties. Such amino acid substitutions may generally be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. Typically, conservative substitutions have little or no effect on the activity of a protein or polypeptide.

[0036] In the present invention, the term "corresponding to" refers to an amino acid residue at a recited position in a polypeptide, or an amino acid residue similar or identical or homologous to a recited residue in a polypeptide. Identifying an amino acid at a corresponding position may be determining the particular amino acid of a sequence that references a particular sequence. As used herein, a "corresponding region" generally refers to a similar or corresponding position in a related or reference protein.

[0037] For example, any amino acid sequence can be aligned with SEQ ID NO: 3, and based thereon, each amino acid residue in the amino acid sequence can be numbered with reference to the numeric position of the corresponding amino acid residue in SEQ ID NO: 3. For example, a sequence alignment algorithm as described herein can identify the position of an amino acid relative to a query sequence (also referred to as a "query sequence"), or the position at which a modification such as a substitution, insertion or deletion occurs.

[0038] For such alignment, for example, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) or the Needle program in the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) can be used, but is not limited thereto. Sequence alignment programs, pairwise sequence comparison algorithms, and the like known in the art can be used as appropriate.

[0039] Another aspect of the invention provides polynucleotides encoding the variants of the invention.

[0040] In the present invention, the term "polynucleotide" refers to a nucleotide polymer in which nucleotide monomers are linked in a long chain by covalent bonds, and refers to a DNA or RNA chain of a certain length or more.

[0041] As an example, the polynucleotide encoding the glutamine hydrolyzing GMP synthetase of the present invention may have or include a sequence encoding the nucleotide sequence of SEQ ID NO: 4. For example, the polynucleotide encoding the glutamine hydrolyzing GMP synthetase may consist of or essentially consist of the sequence of SEQ ID NO: 4.

[0042] The polynucleotides of the present invention may have various modifications in the coding region, taking into account codon degeneracy or preferred codons in the organism in which the variant of the present invention is to be expressed, without changing the amino acid sequence of the variant of the present invention.

[0043] Specifically, the polynucleotide encoding the glutamine hydrolyzing GMP synthetase mutant of the present invention may have or contain a base sequence having a homology or identity of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, and less than 100% to the sequence of SEQ ID NO: 4, or may consist of or essentially consist of a base sequence having a homology or identity of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, and less than 100% to the sequence of SEQ ID NO: 4. In this case, in the sequence having the homology or identity, the codon encoding the amino acid corresponding to the 29th position of SEQ ID NO: 3 may be one of the codons encoding an amino acid other than arginine.

[0044] Furthermore, the polynucleotide of the present invention includes, without limitation, a sequence that can hybridize under stringent conditions with a probe that can be prepared from a known gene sequence, for example, a sequence complementary to the entire or partial sequence of the polynucleotide sequence of the present invention. The term "stringent conditions" refers to conditions that allow specific hybridization between polynucleotides. Such conditions are specifically described in the literature (see J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; FM Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, 9.50-9.51, 11.7-11.8). For example, conditions include conditions under which polynucleotides having high homology or identity, such as polynucleotides having a homology or identity of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, are hybridized with each other, and polynucleotides having lower homology or identity are not hybridized with each other; and conditions under which washing is performed once, specifically two to three times, at a salt concentration and temperature equivalent to the washing conditions for normal Southern hybridization, which are 60°C, 1 x SSC, and 0.1% SDS, specifically 60°C, 0.1 x SSC, and 0.1% SDS, and more specifically 68°C, 1 x SSC, and 0.1% SDS.

[0045] Hybridization requires that two nucleic acids have complementary sequences, even though mismatches between bases are possible depending on the stringency of hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize to each other. For example, with respect to DNA, adenine is complementary to thymine, and cytosine is complementary to guanine. Thus, the polynucleotides of the present invention may also include isolated nucleic acid fragments that are complementary to the entire sequence, as well as substantially similar nucleic acid sequences.

[0046] Specifically, polynucleotides having homology or identity to the polynucleotides of the present invention can be detected using the above-mentioned hybridization conditions including a hybridization step at a Tm value of 55° C. The Tm value may be, but is not limited to, 60° C., 63° C., or 65° C., and can be appropriately adjusted by those skilled in the art depending on the purpose.

[0047] The appropriate stringency for hybridizing such polynucleotides depends on the length of the polynucleotides and the degree of complementation, variables well known in the art (eg, J. Sambrook et al., supra).

[0048] Another aspect of the present invention provides a vector comprising a polynucleotide encoding the variant of the present invention, which may be, but is not limited to, an expression vector for expressing the polynucleotide in a host cell.

[0049] The "vector" of the present invention may include a DNA construct comprising a base sequence of a polynucleotide encoding a target polypeptide operably linked to a suitable expression control region (or expression control sequence) so as to enable expression of the target polypeptide in a suitable host. The expression control region may include a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence controlling the termination of transcription and decoding. After being transformed into a suitable host cell, the vector may replicate or function independently of the host genome, or may be integrated into the genome itself.

[0050] The vector used in the present invention is not particularly limited, and any vector known in the art can be used. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A can be used as phage or cosmid vectors, and pDZ, pBR, pUC, pBluescriptII, pGEM, pTZ, pCL, and pET can be used as plasmid vectors. Specifically, pDZ, pDC, pDCM2, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, and pCC1BAC vectors can be used.

[0051] For example, a polynucleotide encoding a target polypeptide can be inserted into a chromosome through a vector for chromosomal insertion in a cell. The polynucleotide can be inserted into a chromosome by any method known in the art, for example, but not limited to, homologous recombination. A selection marker for checking the presence or absence of insertion into the chromosome may be further included. The selection marker is for selecting cells transformed with the vector, i.e., for checking the presence or absence of insertion of the target nucleic acid molecule, and a marker that confers a selectable phenotype such as drug resistance, auxotrophy, resistance to cytotoxic agents, or expression of a surface polypeptide can be used. In an environment treated with a selective agent, only cells expressing the selection marker survive or show other expression traits, so that transformed cells can be selected.

[0052] The term "transformation" in the present invention means introducing a vector containing a polynucleotide encoding a target polypeptide into a host cell or microorganism so that the polypeptide encoded by the polynucleotide can be expressed in the host cell. The transformed polynucleotide may include all of them, regardless of whether they are inserted and located in the chromosome of the host cell or located outside the chromosome, as long as they can be expressed in the host cell. The polynucleotide may also include DNA and / or RNA encoding the target polypeptide. The polynucleotide may be introduced in any form as long as it can be introduced into the host cell and expressed. For example, the polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a genetic structure containing all elements necessary for its own expression. The expression cassette may usually include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal operably linked to the polynucleotide. The expression cassette may be in the form of a self-replicating expression vector. The polynucleotide may also be introduced into the host cell in its own form and operably linked to a sequence necessary for expression in the host cell, but is not limited thereto.

[0053] In addition, the term "operably linked" means that the polynucleotide sequence is functionally linked to a promoter sequence that initiates and mediates transcription of the polynucleotide encoding the variant of the present invention.

[0054] Another aspect of the invention provides a microorganism comprising a variant of the invention or a polynucleotide encoding the variant.

[0055] The microorganism of the present invention may comprise a mutant of the present invention, a polynucleotide encoding same, or a vector comprising said polynucleotide.

[0056] In the present invention, the term "microorganism (or strain)" includes all wild-type microorganisms and microorganisms that have been genetically modified naturally or artificially, and may be a microorganism in which a specific mechanism has been weakened or strengthened by inserting an exogenous gene or by enhancing or inactivating the activity of an endogenous gene, and may also be a microorganism that contains a genetic modification for producing a desired polypeptide, protein, or product.

[0057] A microorganism of the invention may be, but is not limited to, a microorganism comprising one or more of a variant of the invention, a polynucleotide encoding a variant of the invention, and a vector comprising a polynucleotide encoding a variant of the invention; a microorganism that has been modified to express a variant of the invention or a polynucleotide encoding a variant of the invention; a microorganism (e.g., a recombinant strain) that expresses a variant of the invention or a polynucleotide encoding a variant of the invention; or a microorganism (e.g., a recombinant strain) that has an activity of a variant of the invention.

[0058] The microorganism of the present invention may have the ability to produce purine nucleotides.

[0059] The microorganism of the present invention may be, but is not limited to, a microorganism naturally having glutamine hydrolyzing GMP synthetase or purine nucleotide producing ability; or a parent strain lacking glutamine hydrolyzing GMP synthetase or purine nucleotide producing ability into which the mutant of the present invention or a polynucleotide encoding the mutant (or a vector containing the polynucleotide) has been introduced and / or which has been conferred purine nucleotide producing ability. As an example, the microorganism of the present invention may be a microorganism into which the glutamine hydrolyzing GMP synthetase mutant of the present invention has been introduced and which has been conferred purine nucleotide producing ability. As an example, the microorganism of the present invention may be a microorganism into which the glutamine hydrolyzing GMP synthetase mutant of the present application has been introduced and which has increased purine nucleotide producing ability. However, the present invention is not limited to this.

[0060] As an example, the strain of the present invention is a cell or microorganism transformed with a vector containing a polynucleotide of the present invention or a polynucleotide encoding the mutant of the present application, and expresses the mutant of the present invention. For the purposes of the present invention, the strain of the present invention may include all microorganisms capable of producing purine nucleotides, including the mutant of the present invention. For example, the strain of the present invention may be a recombinant strain having an increased purine nucleotide production ability, in which a polynucleotide encoding the mutant of the present invention is introduced into a natural wild-type microorganism, or a microorganism that produces purine nucleotides, thereby expressing a glutamine hydrolyzing GMP synthetase mutant. The recombinant strain having an increased purine nucleotide production ability may be, but is not limited to, a natural wild-type microorganism or a glutamine hydrolyzing GMP synthetase-unaltered microorganism (i.e., a microorganism expressing a wild-type glutamine hydrolyzing GMP synthetase (SEQ ID NO: 3); or a microorganism that does not express a mutant protein).

[0061] In the present invention, the term "non-mutated microorganism" does not exclude strains containing mutations that may occur naturally in microorganisms, and may refer to a wild-type or naturally occurring strain itself, or a strain before its characteristics are changed by genetic mutation due to natural or artificial factors. For example, the non-mutated microorganism may refer to a strain into which the glutamine hydrolyzing GMP synthase mutant described herein has not been introduced or before it has been introduced. The term "non-mutated microorganism" may be used interchangeably with "strain before mutation," "microorganism before mutation," "non-mutated strain," "non-mutated strain," "non-mutated microorganism," or "reference microorganism."

[0062] In one embodiment, the microorganism of the present invention may be a Corynebacterium microorganism. For example, the microorganism of the present invention is Corynebacterium stationis, Corynebacterium crudilactis, Corynebacterium deserti, Corynebacterium efficiens, Corynebacterium callunae, Corynebacterium glutamicum, Corynebacterium singulare, Corynebacterium halotolerans, Corynebacterium striatum, Corynebacterium ammoniagenes, Corynebacterium ammoniagenes, Corynebacterium pollutisoli, Corynebacterium imitans, Corynebacterium testudinoris or Corynebacterium flavescens. Specifically, the bacterium may be, but is not limited to, Corynebacterium stationis.

[0063] In the present invention, "purine nucleotide" refers to a nucleotide that contains a purine-based structure. Purine nucleotide may be XMP, IMP, GMP or AMP, specifically IMP, XMP or GMP. More specifically, it may be XMP or GMP, but is not limited thereto.

[0064] The present invention relates to "IMP (inosine 5'-monophosphate, 5'-inosinic acid)" and "GMP (guanosine ine-5'-monophosphate, 5'-Guanylic acid) is an intermediate in the nucleic acid biosynthesis metabolic pathway. They play an important physiological role in the body and are widely used in foods, medicines, etc. Specifically, IMP itself is known to produce a beef flavor, while GMP, which is derived from XMP, is known to produce a mushroom flavor, and both substances are known to enhance the flavor of monosodium glutamate (MSG), and are in the spotlight as flavorful nucleic acid seasonings.

[0065] In one embodiment, GMP may be produced by converting XMP, but is not limited thereto. For example, GMP can be produced by converting XMP, the production amount of which is increased, to increase the production amount of GMP, and it is obvious that the GMP is also included in the scope of the present invention.

[0066] "XMP" in the present invention is xanthosine-5'-monophosphate, Also known as 5'-Xanthylic acid, it is produced through the action of IMP dehydrogenase. It can be formed from IMP via the action of GMP synthase or converted to GMP via the action of GMP synthase.

[0067] In the present invention, "microorganisms that produce purine nucleotides" include all wild-type microorganisms and microorganisms that have undergone natural or artificial genetic modification, and are microorganisms in which a specific mechanism has been weakened or strengthened by, for example, inserting an exogenous gene or enhancing or inactivating the activity of an endogenous gene, and may also be microorganisms in which a genetic mutation has occurred or activity has been strengthened in order to produce the desired purine nucleotide.

[0068] The purine nucleotide-producing microorganisms of the present invention, including glutamine hydrolyzing GMP synthetase mutants, can be characterized by having increased productivity of the desired purine nucleotide.

[0069] In one embodiment, the microorganism that produces purine nucleotides or has the ability to produce purine nucleotides in the present invention may be a microorganism in which a portion of a gene in the purine nucleotide biosynthetic pathway is enhanced or weakened, or a portion of a gene in the purine nucleotide degradation pathway is enhanced or weakened.

[0070] The term "attenuation" of a polypeptide activity in the present invention is a concept that includes all of a decrease in activity or no activity compared to the endogenous activity. The attenuation may be mixed with terms such as inactivation, deficiency, down-regulation, decrease, reduction, and attenuation.

[0071] The attenuation may include cases where the activity of the polypeptide itself is reduced or eliminated compared to the activity of the polypeptide originally possessed by the microorganism due to a mutation in the polynucleotide encoding the polypeptide, where the overall polypeptide activity and / or concentration (expression amount) in the cell is lower than that of a wild-type strain due to inhibition of gene expression of the encoding polynucleotide or inhibition of translation into the polypeptide, where the polynucleotide is not expressed at all, and / or where the polypeptide activity is absent despite the expression of the polynucleotide. The "intrinsic activity" refers to the activity of a specific polypeptide originally possessed by a parent strain, a wild-type or a non-transformed microorganism before transformation when the trait is changed due to a genetic mutation caused by natural or artificial factors. This may be used interchangeably with "activity before transformation." The activity of a polypeptide being "inactivated, deficient, reduced, down-regulated, decreased, attenuated" compared to the intrinsic activity means that the activity of a specific polypeptide is decreased compared to that originally possessed by a parent strain or a non-transformed microorganism before transformation.

[0072] Such attenuation of the activity of a polypeptide can be achieved by any method known in the art, including but not limited to, the application of various methods well known in the art (e.g., Nakashima N et al., Bacterial cellular engineering by genome editing and gene silencing. Int J Mol Sci. 2014;15(2):2773-2793, Sambrook et al. Molecular Cloning 2012, etc.).

[0073] Specifically, the attenuation of the polypeptide of the present invention is 1) A deletion of all or part of a gene encoding a polypeptide; 2) modification of an expression control region (or expression control sequence) so that expression of a gene encoding a polypeptide is reduced; 3) modification of the amino acid sequence constituting the polypeptide (e.g., deletion / substitution / addition of one or more amino acids in the amino acid sequence) so as to eliminate or weaken the activity of the polypeptide; 4) modification of a gene sequence encoding a polypeptide such that the activity of the polypeptide is eliminated or attenuated (e.g., deletion / substitution / addition of one or more nucleic acid bases on the nucleic acid base sequence of the polypeptide gene to encode a polypeptide that has been altered such that the activity of the polypeptide is eliminated or attenuated); 5) Coding the initiation codon or 5'-UTR region of a gene transcript encoding a polypeptide Variation in the base sequence; 6) introduction of an antisense oligonucleotide (e.g., antisense RNA) that binds complementary to the transcript of the gene encoding the polypeptide; 7) Addition of a sequence complementary to the Shine-Dalgarno sequence before the Shine-Dalgarno sequence of a gene encoding a polypeptide in order to form a secondary structure to which ribosomes cannot attach; 8) At the 3' end of the ORF (open reading frame) of the gene sequence encoding the polypeptide Addition of a promoter that transcribes in the opposite direction (reverse transcription engineering, RTE); or 9) A combination of two or more selected from the above 1) to 8) may be used, but is not particularly limited thereto.

[0074] For example, the 1) deletion of a part or all of the gene encoding the polypeptide may be removal of the entire polynucleotide encoding the endogenous target polypeptide in the chromosome, replacement with a polynucleotide lacking some nucleotides, or replacement with a marker gene.

[0075] The modification of the expression regulatory region (or expression regulatory sequence) in 2) above may be a mutation in the expression regulatory region (or expression regulatory sequence) caused by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, or may be replaced with a sequence having a weaker activity. The expression regulatory region includes, but is not limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation.

[0076] The modification of the amino acid sequence or polynucleotide sequence in 3) and 4) above may be, but is not limited to, the occurrence of mutations in the sequence of the amino acid sequence of the polypeptide or the sequence of the polynucleotide encoding the polypeptide by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, or the exchange with an amino acid sequence or polynucleotide sequence improved to have a weaker activity or an amino acid sequence or polynucleotide sequence improved to have no activity, so as to weaken the activity of the polypeptide. For example, but not limited to, the expression of a gene can be inhibited or weakened by introducing a mutation in a polynucleotide sequence to form a stop codon.

[0077] Also, the initiation codon or 5'-UT of the gene transcript encoding the polypeptide (5) The modification of the base sequence encoding the R region may be, for example, a substitution with a base sequence encoding another initiation codon that has a lower polypeptide expression rate compared to the endogenous initiation codon, but is not limited to this.

[0078] The introduction of an antisense oligonucleotide (e.g., antisense RNA) that binds complementarily to the transcript of the gene encoding the polypeptide 6) can be carried out by referring to, for example, the literature [Weintraub, H. et al., Antisense-RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) 1986].

[0079] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence before the Shine-Dalgarno sequence of a gene encoding a polypeptide in order to form a secondary structure to which ribosomes cannot attach may disable or slow down mRNA translation.

[0080] 8) 3' of the ORF (open reading frame) of the gene sequence encoding the polypeptide Reverse transcription engineering (RTE) may be used to create an antisense nucleotide complementary to the transcript of the gene encoding the polypeptide, thereby attenuating activity.

[0081] In the present invention, the term "enhancement" of a polypeptide activity means that the activity of the polypeptide is increased compared to the endogenous activity. The term "enhancement" may be used interchangeably with terms such as "activation," "up-regulation," "overexpression," and "increase." Here, the terms "activation," "enhancement," "up-regulation," "overexpression," and "increase" may all include the display of an activity that was not originally possessed, or the display of an activity that is improved compared to the endogenous activity or the activity before transformation. The term "endogenous activity" refers to the activity of a specific polypeptide that was originally possessed by a parent strain or a non-transformed microorganism before transformation, when the trait has been changed by genetic mutation due to natural or artificial factors. This term may be used interchangeably with "activity before transformation." The term "enhancement," "up-regulation," "overexpression," or "increase" of a polypeptide activity compared to the endogenous activity means that the activity and / or concentration (expression level) of a specific polypeptide is improved compared to the activity and / or concentration (expression level) of a specific polypeptide that was originally possessed by a parent strain or a non-transformed microorganism before transformation.

[0082] The enhancement can be achieved by introducing an exogenous polypeptide or by enhancing the activity and / or concentration (expression level) of an endogenous polypeptide. The enhancement of the activity of the polypeptide can be confirmed by an increase in the activity, expression level, or amount of a product secreted from the polypeptide.

[0083] The activity of the polypeptide can be enhanced by various methods well known in the art, and is not limited as long as the activity of the target polypeptide can be enhanced compared to that of the microorganism before modification. Specifically, the activity of the polypeptide can be enhanced by, but is not limited to, genetic engineering and / or protein engineering, which are routine methods in molecular biology and well known to ordinary skilled artisans in the art (e.g., Sitnicka et al. Functional Analysis of Genes. Advances in Cell Biology. 2010, Vol. 2. 1-16, Sambrook et al. Molecular Cloning 2012, etc.).

[0084] Specifically, the enhancement of the polypeptide of the present application includes: 1) increasing the intracellular copy number of a polynucleotide encoding a polypeptide; 2) replacing the expression regulatory region of a gene on a chromosome that encodes a polypeptide with a sequence with a strong activity; 3) a modification of the nucleotide sequence encoding the initiation codon or the 5'-UTR region of a gene transcript encoding a polypeptide; 4) modifying the amino acid sequence of the polypeptide so as to enhance the activity of the polypeptide; 5) modifying a polynucleotide sequence encoding a polypeptide so as to enhance the activity of the polypeptide (e.g., modifying the polynucleotide sequence of the polypeptide gene so as to encode a polypeptide modified so as to enhance the activity of the polypeptide); 6) introduction of a foreign polypeptide exhibiting a polypeptide activity or a foreign polynucleotide encoding the same; 7) codon optimization of a polynucleotide encoding a polypeptide; 8) analyzing the tertiary structure of a polypeptide and selectively altering or chemically modifying exposed sites; or 9) A combination of two or more selected from the above 1) to 8) may be used, but is not particularly limited thereto.

[0085] More specifically, The 1) increase in the intracellular copy number of the polynucleotide encoding the polypeptide may be achieved by introducing into the host cell a vector to which the polynucleotide encoding the polypeptide is operably linked and which can replicate and function independently of the host. Alternatively, the polynucleotide encoding the polypeptide may be introduced into a chromosome in the host cell at one or more copies. The introduction into the chromosome may be achieved by, but is not limited to, introducing into the host cell a vector capable of inserting the polynucleotide into the chromosome in the host cell. The vector is as described above.

[0086] The replacement of the gene expression regulatory region (or expression regulatory sequence) on the chromosome encoding the polypeptide with a sequence having a stronger activity may be, for example, the occurrence of a mutation in the sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, so as to further enhance the activity of the expression regulatory region, or the replacement with a sequence having a stronger activity. The expression regulatory region may include, but is not limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and decoding. As an example, the original promoter may be replaced with a strong promoter, but is not limited to these.

[0087] Examples of known strong promoters include, but are not limited to, CJ1 to CJ7 promoters (U.S. Patent US 7662943 B2), lac promoter, trp promoter, trc promoter, tac promoter, lambda phage PR promoter, PL promoter, tet promoter, gapA promoter, SPL promoter, SPL13 (sm3) promoter (U.S. Registered Patent US 10584338 B2), O2 promoter (U.S. Registered Patent US 10273491 B2), tkt promoter, and yccA promoter.

[0088] The modification of the nucleotide sequence encoding the start codon or 5'-UTR region of the gene transcript encoding the polypeptide (3) may be, for example, but is not limited to, replacement with a nucleotide sequence encoding another start codon that has a higher polypeptide expression rate than the endogenous start codon.

[0089] The modification of the amino acid sequence or polynucleotide sequence in 4) and 5) may be, but is not limited to, a mutation in the sequence of the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, so as to enhance the activity of the polypeptide, or an amino acid sequence or polynucleotide sequence improved to have stronger activity or an amino acid sequence or polynucleotide sequence improved to increase activity. The replacement may be, but is not limited to, specifically, by inserting the polynucleotide into a chromosome by homologous recombination. The vector used in this case may further include a selection marker for checking whether or not the chromosome is inserted. The selection marker is as described above.

[0090] The introduction of a foreign polynucleotide exhibiting the activity of the polypeptide 6) may be the introduction of a foreign polynucleotide encoding a polypeptide exhibiting the same / similar activity as the polypeptide into a host cell. The foreign polynucleotide is not limited in origin or sequence as long as it exhibits the same / similar activity as the polypeptide. The method used for the introduction can be a known transformation method appropriately selected by those skilled in the art, and the introduced polynucleotide may be expressed in a host cell to produce a polypeptide, and its activity may be increased.

[0091] The codon optimization of a polynucleotide encoding a polypeptide (7) may be that of an endogenous polynucleotide that is codon-optimized to increase transcription or translation in a host cell, or that of an exogenous polynucleotide that is codon-optimized to optimize transcription or translation in a host cell.

[0092] The above 8) analyzing the tertiary structure of a polypeptide and selecting and modifying or chemically modifying an exposed site may involve, for example, comparing sequence information of a polypeptide to be analyzed with a database storing sequence information of known proteins, determining template protein candidates according to the degree of sequence similarity, confirming the structure based on the sequence information, and selecting and modifying an exposed site to be modified or chemically modified.

[0093] Such enhanced polypeptide activity may refer to, but is not limited to, an increase in the activity or concentration of the corresponding polypeptide expressed relative to the activity or concentration of the polypeptide expressed in a wild-type or unaltered microbial strain, or an increase in the amount of a product produced from the polypeptide.

[0094] In the microorganism of the present invention, partial or total modification of a polynucleotide may be induced by (a) homologous recombination using a vector for chromosomal insertion in the microorganism or genome editing using engineered nuclease (e.g., CRISPR-Cas9) and / or (b) treatment with light and / or chemicals such as ultraviolet light and radiation, but is not limited thereto. The method for partial or total modification of the gene may include a method using DNA recombination technology. For example, a nucleotide sequence or vector containing a nucleotide sequence homologous to a target gene may be injected into the microorganism to cause homologous recombination, thereby causing partial or total deletion of the gene. The injected nucleotide sequence or vector may contain a dominant selection marker, but is not limited thereto.

[0095] Another aspect of the present invention provides a method for producing purine nucleotides, comprising the step of culturing a microorganism containing the variant of the present invention or a polynucleotide encoding same.

[0096] The method for producing purine nucleotides of the present invention may comprise the step of culturing in a medium a microorganism containing a variant of the present invention or a polynucleotide encoding the variant or a vector containing the polynucleotide.

[0097] In the present invention, the term "culture" means growing the microorganism of the present invention under appropriately controlled environmental conditions. The culture process of the present invention can be carried out according to suitable media and culture conditions known in the art. Such a culture process can be easily adjusted and used by those skilled in the art depending on the selected strain. Specifically, the culture may be, but is not limited to, a batch, continuous and / or fed-batch culture.

[0098] In the present invention, the term "culture medium" refers to a substance containing a mixture of nutrients required for culturing the microorganism of the present application as the main components, and supplies nutrients such as water essential for survival and growth, growth factors, etc. Specifically, the medium and other culture conditions used for culturing the microorganism of the present invention can be any medium used for culturing ordinary microorganisms without any particular limitation, and the microorganism of the present invention can be cultured under aerobic conditions in an ordinary medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compounds, amino acids and / or vitamins, etc., while controlling the temperature, pH, etc.

[0099] For example, culture media for Corynebacterium strains can be found in the literature ["Manual of Methods for General Bacteriology" by the American Society for Bacteriology (Washington DC, USA, 1981)].

[0100] In the present invention, the carbon source may include carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc.; organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc. In addition, natural organic nutrient sources such as starch hydrolysates, molasses, blackstrap molasses, rice bran, cassava, bagasse, and corn steeping liquid may be used, specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted into reducing sugars) may be used, and other suitable carbon sources may be used in various ways without limitation. These carbon sources may be used alone or in combination of two or more, and are not limited thereto.

[0101] The nitrogen source may be an inorganic nitrogen source such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.; an organic nitrogen source such as amino acids such as glutamic acid, methionine, glutamine, etc., peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steeping liquid, casein hydrolysate, fish or its decomposition products, defatted soybean cake or its decomposition products, etc. These nitrogen sources may be used alone or in combination of two or more kinds, and are not limited thereto.

[0102] The phosphorus source may include potassium monophosphate, potassium diphosphate, or the corresponding sodium-containing salts. The inorganic compounds may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, and may also include amino acids, vitamins, and / or appropriate precursors. These components or precursors may be added to the medium in a batch or continuous manner. However, they are not limited thereto.

[0103] In addition, during the cultivation of the microorganism of the present invention, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. can be added to the medium in an appropriate manner to adjust the pH of the medium. In addition, during the cultivation, foam generation can be suppressed using an antifoaming agent such as fatty acid polyglycol ester, etc. In addition, in order to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas can be injected into the medium, and in order to maintain the anaerobic and microaerobic states, no gas can be injected or nitrogen, hydrogen or carbon dioxide gas can be injected, but this is not limited thereto.

[0104] In the culture of the present invention, the culture temperature can be maintained at 20 to 45° C., specifically 25 to 40° C., and the culture can be performed for about 10 to 160 hours, but is not limited thereto.

[0105] The purine nucleotides produced by the culture of the present invention may be secreted into the medium or may remain intracellularly.

[0106] The method for producing purine nucleotides of the present invention may further include a step of preparing a microorganism of the present invention, a step of preparing a medium for culturing the microorganism, or a combination thereof (in any order), for example, prior to the culturing step.

[0107] The method for producing purine nucleotides of the present invention may further include a step of recovering purine nucleotides from the culture medium (cultured medium) or the microorganism. The recovery step may be further included after the culturing step.

[0108] The recovery may be a collection of the desired purine nucleotide using an appropriate method known in the art using the culture method of the microorganism of the present invention, such as a batch, continuous or fed-batch culture method, etc. For example, centrifugation, filtration, treatment with a crystallized protein precipitant (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, various chromatographies such as molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, HPLC, or a combination of these methods can be used, and the desired purine nucleotide can be recovered from the medium or the microorganism using an appropriate method known in the art.

[0109] In addition, the method for producing purine nucleotides of the present invention may further include a purification step. The purification can be performed using a suitable method known in the art. For example, when the method for producing purine nucleotides of the present invention includes both a recovery step and a purification step, the recovery step and the purification step can be performed continuously or discontinuously regardless of the order, or can be performed simultaneously or integrated into one step, but are not limited thereto.

[0110] For example, the method for producing GMP in the present invention may further include a step of converting XMP to GMP. In the method for producing GMP in the present invention, the step of converting may be further included after the step of culturing or the step of recovering. The step of converting may be performed using a suitable method known in the art. For example, the conversion may be performed using a coryneform microorganism, Escherichia coli, or 5'-xanthylic acid aminase (e.g., KR 10-0655902 B1, US 2013-0095529 A1, etc.), but is not limited thereto.

[0111] In the method of the present invention, the mutant, polynucleotide, vector, strain, purine nucleotide, etc. are as described in other embodiments above.

[0112] Another aspect of the present invention is to provide a composition for producing purine nucleotides, comprising a variant of the present application, a polynucleotide encoding the variant, a vector comprising the polynucleotide, or a microorganism comprising a polynucleotide of the present invention; a medium in which these have been cultured; or a combination thereof.

[0113] The composition of the present invention may further contain any suitable excipient that is commonly used in compositions for producing purine nucleotides, and such excipients may be, for example, preservatives, wetting agents, dispersing agents, suspending agents, buffers, stabilizers, or isotonicity agents, but are not limited thereto.

[0114] In the composition of the present invention, the mutant, polynucleotide, vector, microorganism, medium, purine nucleotide, etc. are as described in the other aspects above.

[0115] Another aspect of the present invention is to provide a method for increasing the ability of a microorganism to produce purine nucleotides, comprising the step of transforming the microorganism to express a variant of the present invention.

[0116] In the method of the present invention, the mutant, polynucleotide, vector, microorganism, medium, purine nucleotide, etc. are as described in the other aspects above.

[0117] Another aspect of the present invention provides the use of the mutant of the present invention in the production of purine nucleotides.

[0118] Another aspect of the present invention provides the use of a microorganism containing a mutant of the present invention, a polynucleotide encoding it, or a vector containing it in the production of purine nucleotides.

[0119] The mutant, polynucleotide, vector, microorganism, etc. are as described in other embodiments.

[0120] The present invention will be described in more detail with reference to the following examples and experimental examples. However, these examples and experimental examples are provided to illustrate the present application, and the scope of the present invention is not limited to these examples and experimental examples. EXAMPLES

[0121] Example 1: Preparation of guaA synthetase weakened mutants To discover guaA mutants for XMP production, we constructed a mutation library of guaA, the gene encoding it.

[0122] Example 1-1. Construction of a vector containing guaA To prepare a guaA mutant library, we first prepared a recombinant vector containing guaA. PCR was performed using the chromosome of Corynebacterium stathionis ATCC6872 as a template and the primers shown in SEQ ID NO:5 and SEQ ID NO:6. The amplified product was cloned into pCR2.1 vector using TOPO Cloning Kit (Invitrogen), and the resulting vector was named pCR-guaA.

[0123] [Table 1]

[0124] Example 1-2: Construction of a guaA mutation library A guaA mutation library was prepared using the pCR-guaA vector prepared in Example 1-1 as a template. The library was randomly mutated using an error-prone PCR kit (clontech DiversifyR PCR Random Mutagenesis Kit) and primers of SEQ ID NO: 7 and SEQ ID NO: 8 according to the manufacturer's manual to obtain guaA mutation PCR products with different sequences. The amplified products were cloned using a TOPO Cloning Kit (Invitrogen), transformed into E. coli DH5α, and smeared on LB solid medium containing kanamycin (25 mg / L). The transformed E. coli colonies were collected and plasmids were extracted, which was named pCR-guaA-library.

[0125] [Table 2]

[0126] Example 1-3: Evaluation of the constructed library and selection of strains The pCR-guaA-library prepared in Example 1-2 was transformed into the wild-type strain of Corynebacterium steatoniais ATCC6872 by electroporation, and then 5,000 colonies of the strain into which the mutant gene was inserted were obtained by smearing on a nutrient medium containing 25 mg / L kanamycin. Each colony was named C.st ATCC6872_pCR_guaA(mt)1 to C.st ATCC6872_pCR_guaA(mt)5000.

[0127] - Nutrient medium: peptone 1%, meat juice 1%, sodium chloride 0.25%, yeast extract 1%, adenine 150mg / L, guanine 150mg / L, agar 2%, pH 7.2 (based on 1 liter of distilled water)

[0128] The 5,000 colonies thus obtained were each autoclaved and inoculated into 100 μl of seed medium containing kanamycin (25 mg / L), and cultured in a 96-deep well plate at 30°C and 1,200 rpm for 24 hours using a microplate shaker (TAITEC) to use as the seed culture. 320 μl of autoclaved fermentation medium (240 μl of main medium + 80 μl of separate sterilized medium) was dispensed into a 96-deep well plate, and 15 μl of seed culture medium was inoculated into each well, followed by shaking culture for 72 hours under the same conditions as above.

[0129] To analyze the amount of XMP produced in the culture, after the culture was completed, 640 μl of sterile water was added to the culture and centrifuged at 4000 rpm for 15 minutes, and 3 μl of the supernatant was transferred to a 96-well UV-plate containing 297 μl of distilled water. The plates were then shaken for 30 seconds using a microplate reader, and the absorbance was measured at 25°C and 260 nm using a spectrophotometer. Ten mutant colonies with increased absorbance relative to the wild-type strain were selected. The remaining colonies showed similar or decreased absorbance compared to the control group.

[0130] The 10 selected strains were repeatedly examined for XMP production by measuring absorbance in the same manner as described above, and one strain (C.st ATCC6872_pCR_guaA(mt)726) was selected that had significantly improved XMP production ability compared to the wild-type strain.

[0131] Fermentation titer evaluation was performed to verify the effectiveness of the final selected strains.

[0132] 14 ml tubes containing 2.5 ml of the following seed medium were inoculated with Corynebacterium stationis ATCC 6872 wild-type strain and the selected C. st ATCC 6872_pCR_guaA(mt)726 strain, and cultured with shaking at 170 rpm for 24 hours at 30°C. 0.7 ml of the seed culture solution was inoculated into a 250 ml Erlenmeyer flask containing 32 ml of the following production medium (24 ml of this medium + 8 ml of separately sterilized medium), and cultured with shaking at 170 rpm for 75 hours at 30°C.

[0133] The compositions of the above-mentioned seed medium, this medium, and the separately sterilized medium are as follows.

[0134] <Seed medium for XMP flask> Glucose 30 g / L, Peptone 15 g / L, Yeast extract 15 g / L, Sodium chloride 2.5 g / L, Urea 3 g / L, Adenine 150 mg / L, Guanine 150 mg / L, pH 7.0 (based on 1 liter of distilled water)

[0135] <XMP flask production medium (this medium)> Glucose 50 g / L, Magnesium sulfate 10 g / L, Yeast extract 3 g / L, Calcium chloride 100 mg / L, Iron sulfate 20 mg / L, Manganese sulfate 10 mg / L, Zinc sulfate 10 mg / L, Copper sulfate 0.8 mg, Histidine 20 mg / L, Cysteine 15 mg / L, β-Alanine 15 mg / L, Biotin 100 μg / L, Thiamine 5 mg / L, Adenine 50 mg / L, Guanine 25 mg / L, Niacin 15 mg / L, pH 7.0 (based on 1 liter of distilled water)

[0136] <XMP flask production medium (separately sterilized medium)> Potassium dihydrogen phosphate 18 g / L, Dipotassium hydrogen phosphate 42 g / L, Urea 7 g / L, Ammonium sulfate 5 g / L (based on 1 liter of distilled water)

[0137] After the cultivation, the production amount of XMP was measured by the method using HPLC, and the results are as shown in Table 3 below.

[0138]

Table 3

[0139] As shown in Table 3, it was confirmed that the wild-type strain C. st ATCC6872_pCR_guaA(mt)726 produced XMP at a concentration of 4.83 g / L.

[0140] Examples 1-4: Confirmation of mutations through gene sequencing In order to confirm the guaA mutant sequence of the C.st ATCC6872_pCR_guaA(mt)726 strain, PCR and base sequence analysis were performed on the C.st ATCC6872_pCR_guaA(mt)726 strain using primers of SEQ ID NO: 8 and SEQ ID NO: 9. As a result of comparison with the wild-type strain guaA gene sequence, it was confirmed that the 29th amino acid of the C.st ATCC6872_pCR_guaA(mt)726 strain guaA gene contained a mutation in which arginine was replaced with cysteine ​​(the 85th nucleotide was replaced with c to t: SEQ ID NO: 2).

[0141] The confirmed mutant sequences are shown in Table 4 below.

[0142] [Table 4]

[0143] Therefore, in the following examples, we sought to determine whether the guaA mutation affects the production of XMP.

[0144] Example 2: Confirmation of the effect of guaA mutant Example 2-1: Construction of a vector for expression of guaA mutants To confirm the effect of a mutant in which arginine at position 29 of the guaA enzyme amino acid sequence was replaced with cysteine ​​(R29C; SEQ ID NO: 1) on XMP production, a vector for constructing an expression strain was constructed as follows using the plasmid pDCM2 (Republic of Korea Publication No. 10-2020-0136813) for inserting and exchanging genes in the Corynebacterium chromosome.

[0145] PCR was performed using the primer pairs SEQ ID NO:10 and SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13, with the chromosome of Corynebacterium stathionis ATCC6872 as a template. SolgTM Pfu-X DNA polymerase was used as the polymerase, and the PCR amplification conditions were denaturation at 95°C for 5 minutes, followed by denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 60 seconds, repeated 30 times, and then polymerization at 72°C for 5 minutes to obtain each PCR product. The amplified product was mixed with pDCM2 vector, which had been prepared in advance by cleaving with SmaI restriction enzyme, and cloned using the Gibson assembly method (DG Gibson et al., NATURE METHODS, VOL.6 NO.5, MAY 2009, NEBuilder HiFi DNA Assembly Master Mix) to obtain a recombinant plasmid, which was named pDCM2-guaA(R29C). Cloning was performed by mixing Gibson assembly reagent and each gene fragment in calculated molar amounts and storing at 50°C for 1 hour.

[0146] Example 2-2: Construction of a strain expressing a guaA mutant The Corynebacterium stationis ATCC6872 strain was transformed with the pDCM2-guaA(R29C) vector prepared in the above Example by electroporation, and the strain in which the vector was inserted into the chromosome by recombination of the homologous sequence was selected in a medium containing 25 mg / L of kanamycin. The selected primary strain was again subjected to a second cross-over, and a strain in which the target gene mutation was introduced was selected. The presence or absence of gene mutation in the final transformed strain was confirmed by PCR and base sequence analysis using the primer pair of SEQ ID NO: 14 and SEQ ID NO: 15, and the strain was named C.st ATCC6872::guaA(R29C).

[0147] Example 2-3: Comparison of XMP production ability of guaA mutant expressing strains The XMP producing ability of the C.st ATCC6872::guaA(R29C) strain and the wild-type strain prepared in Example 2-2 was confirmed by the fermentation titer evaluation method in Example 1-3. After the cultivation, the amount of XMP produced was measured using HPLC, and the cultivation results are shown in Table 5 below.

[0148] The above experiment was repeated three times, and the average analytical results are shown in Table 5 below.

[0149] [Table 5]

[0150] As in Table 5, it was confirmed that the C. st ATCC6872::guaA(R29C) strain produced an XMP concentration of 5.21 g / L.

[0151] The C. st ATCC6872::guaA(R29C) strain was named CN02-2299 and deposited at the Korea Microorganism Collection, a depository under the Budapest Treaty, on August 9, 2021, and was assigned the accession number KCCM13029P.

[0152] Example 3: Substitution of amino acids in the guaA mutation with other amino acids Example 3-1: Construction of a vector for inserting guaA mutant amino acid substitutions The above example confirmed that XMP can be produced by the guaA(R29C) mutation. In order to confirm the importance of the position of the guaA mutation, a vector was prepared in which the 29th amino acid was replaced with another amino acid, and it was confirmed whether it had an effect on XMP production ability. Site-directed mutagenesis was performed using the pDCM2-guaA(R29C) vector prepared in Example 2-1 as a template.

[0153] Specifically, the primer pairs are SEQ ID NO:10 and SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:13, the primer pairs are SEQ ID NO:10 and SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:13, the primer pairs are SEQ ID NO:10 and SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:13, the primer pairs are SEQ ID NO:10 and SEQ ID NO:22, SEQ ID NO:23 and SEQ ID NO:13, the primer pairs are SEQ ID NO:10 and SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:13, the primer pairs are SEQ ID NO:10 and SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:13, the primer pairs are SEQ ID NO:10 and SEQ ID NO:28, SEQ ID NO:29 and SEQ ID NO:13, the primer pairs are SEQ ID NO:10 and SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:13, the primer pairs are SEQ ID NO:10 and SEQ ID NO:32, SEQ ID NO:33 and SEQ ID NO:13, the primer pairs are SEQ ID NO:10 and SEQ ID NO: PCR was performed using the primer pairs of SEQ ID NO:34, SEQ ID NO:35 and SEQ ID NO:13, SEQ ID NO:10 and SEQ ID NO:36, SEQ ID NO:37 and SEQ ID NO:13, SEQ ID NO:10 and SEQ ID NO:38, SEQ ID NO:39 and SEQ ID NO:13, SEQ ID NO:10 and SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:13, SEQ ID NO:10 and SEQ ID NO:42, SEQ ID NO:43 and SEQ ID NO:13, SEQ ID NO:10 and SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:13, SEQ ID NO:10 and SEQ ID NO:46, SEQ ID NO:47 and SEQ ID NO:13, SEQ ID NO:10 and SEQ ID NO:48, SEQ ID NO:49 and SEQ ID NO:13, SEQ ID NO:10 and SEQ ID NO:50, SEQ ID NO:51 and SEQ ID NO:13, respectively, where the polymerase was SolgTM. Pfu-X DNA polymerase was used, and the PCR amplification conditions were denaturation at 95°C for 5 minutes, followed by denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 60 seconds, repeated 30 times, and then polymerization reaction at 72°C for 5 minutes to obtain each PCR product. Each of the above amplification products was previously digested with SmaI restriction enzyme, mixed with the prepared pDCM2 vector, and cloned using the Gibson assembly method to obtain recombinant plasmids. The plasmid information thus obtained is shown in Table 6. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in the calculated molar amount and storing at 50°C for 1 hour.

[0154] [Table 6]

[0155] Example 3-2: Preparation of strains in which the guaA mutation has been replaced with other amino acids and comparison of XMP production ability The 18 kinds of mutation introduction vectors prepared in Example 3-1 were transformed into wild-type Corynebacterium stathionis ATCC6872 strain by electroporation, and the strains in which the vectors were inserted into the chromosomes by recombination of the homologous sequences were selected in a medium containing 25 mg / L of kanamycin. The selected primary strains were again subjected to a second cross-over to select the strains in which the mutations were introduced into the target genes. The presence or absence of gene mutations in the final transformed strains was confirmed by PCR and base sequence analysis using the primer pair of SEQ ID NO: 14 and SEQ ID NO: 15, and the strain names according to the inserted mutations are shown in Table 7 below.

[0156] [Table 7]

[0157] The prepared strain, C.st ATCC6872::guaA(R29C) strain, and wild-type strain were cultured according to the method for evaluating fermentation titer in Examples 1-3, and the XMP concentration was analyzed. The experiment was repeated three times, and the average values ​​of the analysis results are shown in Table 8 below.

[0158] [Table 8]

[0159] Referring to Table 8, it was confirmed that in the case of a strain containing guaA in which the 29th amino acid of the amino acid sequence encoded by the guaA gene is replaced with another amino acid other than arginine, XMP is produced more than in the wild-type strain. That is, the 29th amino acid of the amino acid sequence encoded by the guaA gene is a major mutation position in the production of XMP, and more specifically, it was confirmed that when the 29th amino acid of the amino acid sequence encoded by the guaA gene is replaced with another amino acid (cysteine, glycine, phenylalanine, serine, tyrosine, tryptophan, isoleucine, valine, proline, threonine, alanine, aspartic acid, asparagine, histidine, leucine, methionine, glutamine, lysine, and glutamic acid) instead of arginine, the XMP production amount of the microorganism containing it can be significantly increased.

[0160] This indicates that a mutant in which the 29th amino acid of guaA is substituted with another amino acid can be useful for producing purine nucleotides.

[0161] Example 4: Confirmation of GMP production ability of guaA mutant expressing strain GMP production was confirmed by the following method using the XMP culture medium of XMP-producing strain C. st ATCC6872::guaA(R29C) (see Korean Patent Publication No. KR 10-0655902 B1, U.S. Patent Publication No. US 2013-0095529 A1).

[0162] The C.st ATCC6872::guaA(R29C) strain was cultured using the method for evaluating fermentation titer in Example 1-3. After the culture was completed, the amount of XMP produced was measured using a method using HPLC. In order to convert the produced XMP to GMP, the following conversion reaction additives and E. coli XMP aminase were added to the Erlenmeyer flask fermentation liquid, and the conversion reaction was carried out at 40°C for 2.5 hours.

[0163] <Conversion reaction additives> Phytic acid 1.8g / L, magnesium sulfate 4.8g / L, nymeen 3ml / L, xylene 2%, adenine 100mg / L, sodium hydrogen phosphate (Na2HPO4) 7.7g / L, glutamine 2g / L, glucose 46g / L

[0164] As a result of the above experiment, the conversion rate, which means the amount of GMP produced relative to the amount of XMP consumed, is shown in Table 9.

[0165] [Table 9]

[0166] As shown in Table 9, it was confirmed that 3.54 g / L of GMP was produced through the conversion reaction of XMP produced by the C. st ATCC6872::guaA(R29C) strain.

[0167] As a result, it was confirmed that a mutant in which the 29th amino acid of guaA is replaced with another amino acid increases GMP production, indicating that the mutant provided by the present invention can be useful for producing purine nucleotides.

[0168] From the above description, it will be understood by those skilled in the art to which the present invention pertains that the present invention may be embodied in other specific forms without changing the technical idea or essential features of the present invention. In this regard, it should be understood that the above-described embodiments are merely illustrative and not limiting. The scope of the present invention should be interpreted as including any modified or altered forms derived from the meaning and scope of the claims below, and their equivalent concepts, rather than the above detailed description.

Claims

[Claim 1] A mutant glutamine hydrolyzing GMP synthase in which the amino acid corresponding to the 29th position of SEQ ID NO:3 is replaced with another amino acid.

Citation Information

Patent Citations

  • Novel promoter and purine nucleotide production method using same

    EP3722430A1

  • Corynebacterium ammoniagenes cjxcv24 KCCM-10693p having high activity of convertion of XMP to gmp

    KR100655902B1

  • The method of producing L-tryptophan using enhancing the activity of prephenate dehydratase

    KR1020200136813A

  • Promoter and uses thereof

    US10273491B2

  • Promoter and use thereof

    US10584338B2